In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to treat advanced ...

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

Daiichi Sankyo (OTCPK:DSKYF ... Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer.

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Read Next: AstraZeneca Aims to Restor TOKYO & BASKING RIDGE, N.J., January 13, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire ...

MUNICH & CAMBRIDGE, England--(BUSINESS WIRE)--A new survey sponsored by Daiichi Sankyo and AstraZeneca reveals that there is a need for more readily available information on breast cancer ...

Sales of Daiichi Sankyo Espha products are no longer recorded ... milestone payments etc related to the alliance with AstraZeneca and US MRK increased by JPY25.3 billion mainly due to the ...